CRISPR Therapeutics Stock Forecast, Price & News

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRISPR Therapeutics stock.
View analyst ratings for CRISPR Therapeutics or view top-rated stocks.

Wall Street analysts have given CRISPR Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CRISPR Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

CRISPR Therapeutics saw a increase in short interest in August. As of August 13th, there was short interest totaling 2,940,000 shares, an increase of 14.0% from the July 29th total of 2,580,000 shares. Based on an average trading volume of 1,260,000 shares, the days-to-cover ratio is currently 2.3 days. Currently, 4.6% of the shares of the company are sold short.
View CRISPR Therapeutics' Short Interest.

CRISPR Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for CRISPR Therapeutics.

CRISPR Therapeutics AG (NASDAQ:CRSP) announced its quarterly earnings data on Thursday, July, 29th. The company reported $9.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $3.52 by $5.92. The firm had revenue of $900.70 million for the quarter, compared to analyst estimates of $678.05 million. CRISPR Therapeutics had a trailing twelve-month return on equity of 24.08% and a net margin of 49.52%.
View CRISPR Therapeutics' earnings history.

CRISPR Therapeutics' stock was trading at $43.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CRSP shares have increased by 170.9% and is now trading at $117.25.
View which stocks have been most impacted by COVID-19.

17 brokerages have issued 1 year price targets for CRISPR Therapeutics' stock. Their forecasts range from $110.00 to $210.00. On average, they anticipate CRISPR Therapeutics' share price to reach $160.69 in the next twelve months. This suggests a possible upside of 37.0% from the stock's current price.
View analysts' price targets for CRISPR Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to CRISPR Therapeutics include Seagen (SGEN), Bio-Techne (TECH), Novozymes A/S (NVZMY), Repligen (RGEN), Novavax (NVAX), argenx (ARGX), QIAGEN (QGEN), Acceleron Pharma (XLRN), Neurocrine Biosciences (NBIX), Vir Biotechnology (VIR), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Exelixis (EXEL), Beam Therapeutics (BEAM) and Twist Bioscience (TWST).
View all of CRSP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

CRISPR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (10.20%), Capital International Investors (6.02%), Nikko Asset Management Americas Inc. (4.44%), Price T Rowe Associates Inc. MD (1.56%), Macquarie Group Ltd. (1.52%) and BlackRock Inc. (1.38%). Company insiders that own CRISPR Therapeutics stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni and Tony W Ho.
View institutional ownership trends for CRISPR Therapeutics.

CRSP stock was sold by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, ARK Investment Management LLC, Franklin Resources Inc., Morgan Stanley, Morgan Stanley, Capital International Investors, Nikko Asset Management Americas Inc., and BlackRock Inc.. Company insiders that have sold CRISPR Therapeutics company stock in the last year include Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, and Tony W Ho.
View insider buying and selling activity for CRISPR Therapeutics or view top insider-selling stocks.

CRSP stock was bought by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Discovery Value Fund, Ikarian Capital LLC, Himension Fund, Bank of America Corp DE, Bank of America Corp DE, Parallax Volatility Advisers L.P., and American Century Companies Inc..
View insider buying and selling activity for CRISPR Therapeutics or or view top insider-buying stocks.

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRSP stock can currently be purchased for approximately $117.25.

CRISPR Therapeutics has a market capitalization of $8.93 billion and generates $720,000.00 in revenue each year. The company earns $-348,860,000.00 in net income (profit) each year or ($5.29) on an earnings per share basis.

CRISPR Therapeutics employs 410 workers across the globe.

The official website for CRISPR Therapeutics is www.crisprtx.com.

CRISPR Therapeutics is headquartered at BAARERSTRASSE 14, ZUG V8, CH-6300.

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at (141) 561-3277 or via email at [email protected].